Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Peptides — Metabolic

Retatrutide

An investigational triple agonist at the GLP-1, GIP and glucagon receptors studied in early-phase weight-management trials.

Education Hub

Pre-clinical mechanism

Single peptide engineered for balanced activity at three incretin/glucagon receptors. Pre-clinical and phase-2 data describe additive effects on weight reduction beyond dual-agonist comparators.

Key pre-clinical findings

  • Phase-2 trial in adults with obesity (48 weeks): mean weight change up to -24.2% at the highest dose vs -2.1% with placebo (Jastreboff et al., 2023).

Primary literature

Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

Jastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer